JNM Editors’ Choice Awards for 2023

Johannes Czernin

doi:10.2967/jnumed.124.267935

Each year the associate editors and editorial board of The Journal of Nuclear Medicine (JNM) work with me to select outstanding contributions to the journal for recognition at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The JNM Editors’ Choice Awards for articles published in the journal in 2023 were chosen by anonymous vote from a group of diverse, high-quality, and cutting-edge submissions. This year, both awardees’ articles focused on fibroblast activation protein−related research, an area of extraordinary promise and interest, with implications for theranostic innovation across a wide range of cancers and in promising cardiac and other applications.

Johanna Diekmann

Spencer D. Lindeman

In the category of best clinical article, the award went to Johanna Diekmann, from the Hannover Medical School (Germany), and coauthors Jonas Neuser, Manuel Röhrich, Thorsten Derlin, Carolin Zwadlo, Tobias Koenig, Desiree Weiberg, Felix Jäckle, Tibor Kempf, Tobias L. Ross, Jochen Tillmanns, James T. Thackeray, Julian Widder, Uwe Haberkorn, Johann Bauersachs, and Frank M. Bengel for “Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study” (J Nucl Med. 2023;64:1279–1286). This contribution was also named the best overall article in the journal for 2023.

Spencer D. Lindeman, from Purdue University (West Lafayette, IN), and coauthors Ramesh Mukkamala, Autumn Horner, Pooja Tudi, Owen C. Booth, Roxanne Huff, Joshua Hinsey, Anders Hovstadius, Peter Martone, Fenghua Zhang, Madduri Srinivasarao, Abigail Cox, and Philip S. Low were the recipients of the award in the category of best basic science article for “Fibroblast Activation Protein–Targeted Radioligand Therapy for Treatment of Solid Tumors” (J Nucl Med. 2023;64:759–766).

With articles like these, JNM remains the international journal of choice for publishing clinical, basic, and translational research in nuclear medicine, molecular imaging, radiopharmaceutical therapy, and theranostics. This continued success is supported by our hard-working associate editors and editorial board, who collectively encourage our community to embrace the new techniques and agents that will benefit our patients today and enhance future understanding of the potential of molecular medicine.